Format

Send to

Choose Destination
Transl Lung Cancer Res. 2019 Apr;8(2):195-197. doi: 10.21037/tlcr.2019.02.01.

Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer.

Author information

1
David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.

Conflict of interest statement

Conflicts of Interest: A Lisberg Reports the Following Disclosures: Compensated AstraZeneca advisory board attendance, compensated Leica Biosystems consulting, and Funding to his institution from the following companies for clinical trials: Daiichi Sankyo, Calithera Biosciences, AstraZeneca. EB Garon Reports: Funding to his institution from the following companies for clinical trials: AstraZenca, Bristol Myers Squibb, Dynavax, Eli Lilly, Genentech, Iovance, Mirati, Merck, Neon Pfizer, Novartis Honorarium: Dracen.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center